Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
PR Newswire•29/09/2026•07:30 ET
0
Key Highlights
- ➤DCOY-CoV single intranasal dose sustains therapeutic drug levels for up to seven days
- ➤Preclinical data show high drug persistence in upper respiratory and deep lung tissues
- ➤DCOY-CoV targets OC43, 229E, NL63, HKU1, and SARS-CoV-2
- ➤DCOY-CoV expected to enter clinical trials in 2027
Expert Statements
Rick Pierce, Chief Executive Officer of Decoy Therapeutics
“Most antivirals are built for a single virus, but a D-MAV targets conserved fusion mechanisms shared across viral families”
Rick Pierce, Chief Executive Officer of Decoy Therapeutics
“Two of the biggest drivers of real-world therapeutic value are patient compliance and convenience. A single drug that covers multiple coronaviruses and requires only once-weekly administration directly addresses both.”
Barbara Hibner, Chief Scientific Officer and Co-Founder of Decoy Therapeutics
“What we are working toward is a self-administered dose you take once and stop thinking about for the rest of the week”
Barbara Hibner, Chief Scientific Officer and Co-Founder of Decoy Therapeutics
“For fragile patients where a common respiratory virus can cause irreversible lung damage, once-weekly protective coverage represents a crucial breakthrough.”
Michael Lipp, Chief Technology Officer and Co-Founder of Decoy Therapeutics
“presenting these data today, September 29 at the Boulder Peptide Symposium's Peptide Showcase in Napa Valley, California”
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program PR Newswire
Once-Weekly Intranasal Potential: Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.
Get started
Create a free account to read the full story.